Cargando…

The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?

Under physiological conditions, adenosine triphosphate (ATP) is present at low levels in the extracellular milieu, being massively released by stressed or dying cells. Once outside the cells, ATP and related nucleotides/nucleoside generated by ectonucleotidases mediate a high evolutionary conserved...

Descripción completa

Detalles Bibliográficos
Autores principales: Savio, Luiz E. B., de Andrade Mello, Paola, da Silva, Cleide Gonçalves, Coutinho-Silva, Robson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808178/
https://www.ncbi.nlm.nih.gov/pubmed/29467654
http://dx.doi.org/10.3389/fphar.2018.00052
_version_ 1783299416365465600
author Savio, Luiz E. B.
de Andrade Mello, Paola
da Silva, Cleide Gonçalves
Coutinho-Silva, Robson
author_facet Savio, Luiz E. B.
de Andrade Mello, Paola
da Silva, Cleide Gonçalves
Coutinho-Silva, Robson
author_sort Savio, Luiz E. B.
collection PubMed
description Under physiological conditions, adenosine triphosphate (ATP) is present at low levels in the extracellular milieu, being massively released by stressed or dying cells. Once outside the cells, ATP and related nucleotides/nucleoside generated by ectonucleotidases mediate a high evolutionary conserved signaling system: the purinergic signaling, which is involved in a variety of pathological conditions, including inflammatory diseases. Extracellular ATP has been considered an endogenous adjuvant that can initiate inflammation by acting as a danger signal through the activation of purinergic type 2 receptors—P2 receptors (P2Y G-protein coupled receptors and P2X ligand-gated ion channels). Among the P2 receptors, the P2X7 receptor is the most extensively studied from an immunological perspective, being involved in both innate and adaptive immune responses. P2X7 receptor activation induces large-scale ATP release via its intrinsic ability to form a membrane pore or in association with pannexin hemichannels, boosting purinergic signaling. ATP acting via P2X7 receptor is the second signal to the inflammasome activation, inducing both maturation and release of pro-inflammatory cytokines, such as IL-1β and IL-18, and the production of reactive nitrogen and oxygen species. Furthermore, the P2X7 receptor is involved in caspases activation, as well as in apoptosis induction. During adaptive immune response, P2X7 receptor modulates the balance between the generation of T helper type 17 (Th17) and T regulatory (Treg) lymphocytes. Therefore, this receptor is involved in several inflammatory pathological conditions. In infectious diseases and cancer, P2X7 receptor can have different and contrasting effects, being an angel or a demon depending on its level of activation, cell studied, type of pathogen, and severity of infection. In neuroinflammatory and neurodegenerative diseases, P2X7 upregulation and function appears to contribute to disease progression. In this review, we deeply discuss P2X7 receptor dual function and its pharmacological modulation in the context of different pathologies, and we also highlight the P2X7 receptor as a potential target to treat inflammatory related diseases.
format Online
Article
Text
id pubmed-5808178
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58081782018-02-21 The P2X7 Receptor in Inflammatory Diseases: Angel or Demon? Savio, Luiz E. B. de Andrade Mello, Paola da Silva, Cleide Gonçalves Coutinho-Silva, Robson Front Pharmacol Pharmacology Under physiological conditions, adenosine triphosphate (ATP) is present at low levels in the extracellular milieu, being massively released by stressed or dying cells. Once outside the cells, ATP and related nucleotides/nucleoside generated by ectonucleotidases mediate a high evolutionary conserved signaling system: the purinergic signaling, which is involved in a variety of pathological conditions, including inflammatory diseases. Extracellular ATP has been considered an endogenous adjuvant that can initiate inflammation by acting as a danger signal through the activation of purinergic type 2 receptors—P2 receptors (P2Y G-protein coupled receptors and P2X ligand-gated ion channels). Among the P2 receptors, the P2X7 receptor is the most extensively studied from an immunological perspective, being involved in both innate and adaptive immune responses. P2X7 receptor activation induces large-scale ATP release via its intrinsic ability to form a membrane pore or in association with pannexin hemichannels, boosting purinergic signaling. ATP acting via P2X7 receptor is the second signal to the inflammasome activation, inducing both maturation and release of pro-inflammatory cytokines, such as IL-1β and IL-18, and the production of reactive nitrogen and oxygen species. Furthermore, the P2X7 receptor is involved in caspases activation, as well as in apoptosis induction. During adaptive immune response, P2X7 receptor modulates the balance between the generation of T helper type 17 (Th17) and T regulatory (Treg) lymphocytes. Therefore, this receptor is involved in several inflammatory pathological conditions. In infectious diseases and cancer, P2X7 receptor can have different and contrasting effects, being an angel or a demon depending on its level of activation, cell studied, type of pathogen, and severity of infection. In neuroinflammatory and neurodegenerative diseases, P2X7 upregulation and function appears to contribute to disease progression. In this review, we deeply discuss P2X7 receptor dual function and its pharmacological modulation in the context of different pathologies, and we also highlight the P2X7 receptor as a potential target to treat inflammatory related diseases. Frontiers Media S.A. 2018-02-06 /pmc/articles/PMC5808178/ /pubmed/29467654 http://dx.doi.org/10.3389/fphar.2018.00052 Text en Copyright © 2018 Savio, de Andrade Mello, da Silva and Coutinho-Silva. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Savio, Luiz E. B.
de Andrade Mello, Paola
da Silva, Cleide Gonçalves
Coutinho-Silva, Robson
The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
title The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
title_full The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
title_fullStr The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
title_full_unstemmed The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
title_short The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
title_sort p2x7 receptor in inflammatory diseases: angel or demon?
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808178/
https://www.ncbi.nlm.nih.gov/pubmed/29467654
http://dx.doi.org/10.3389/fphar.2018.00052
work_keys_str_mv AT savioluizeb thep2x7receptorininflammatorydiseasesangelordemon
AT deandrademellopaola thep2x7receptorininflammatorydiseasesangelordemon
AT dasilvacleidegoncalves thep2x7receptorininflammatorydiseasesangelordemon
AT coutinhosilvarobson thep2x7receptorininflammatorydiseasesangelordemon
AT savioluizeb p2x7receptorininflammatorydiseasesangelordemon
AT deandrademellopaola p2x7receptorininflammatorydiseasesangelordemon
AT dasilvacleidegoncalves p2x7receptorininflammatorydiseasesangelordemon
AT coutinhosilvarobson p2x7receptorininflammatorydiseasesangelordemon